Nutra Pharma Announces the Launch of MyNyloxin.com for Nyloxin Sales Through Their Network Marketing Distributors
December 06 2013 - 2:22PM
Marketwired
Nutra Pharma Announces the Launch of MyNyloxin.com for Nyloxin
Sales Through Their Network Marketing Distributors
Nutra Pharma Is Announcing the Launch of the www.MyNyloxin.com
Website for the Distribution of the Company's Over-the-Counter
(OTC) Pain Reliever, Nyloxin(R), in the Network Marketing
Channel
CORAL SPRINGS, FL--(Marketwired - Dec 6, 2013) - Nutra
Pharma Corp. (OTCQB: NPHC), a biotechnology company that is
developing treatments for Adrenomyeloneuropathy (AMN), HIV and
Multiple Sclerosis (MS), is announcing that MyNyloxin, a new
Network Marketing company that has the exclusive rights to market
and distribute Nutra Pharma's over-the-counter (OTC) pain reliever,
Nyloxin®, in the Network Marketing channel is launching their
distributor website http://www.mynyloxin.com over the coming
weekend. The website will allow for product sales and information
as well as allowing distributors to sign up and view the Network
Marketing opportunity. Nutra Pharma will continue to market the
products through their retail and Direct Response distributors.
"Pain affects more Americans than diabetes, heart disease and
cancer combined. According to the Institute of Medicine of The
National Academies, chronic pain affects 100 million Americans.
Millions suffer from acute or chronic pain and the effects of pain
exact a tremendous cost on our country in health care costs,
rehabilitation and lost worker productivity, as well as the
emotional and financial burden it places on patients and their
families," stated Dalton Johnson, CEO of MyNyloxin.com.
"MyNyloxin.com is comprised of a group of professional marketers
whom have come together on a mission to spread awareness of
Nyloxin," he continued. "The new MyNyloxin.com website will improve
the lives of people. By providing access to a superior pain relief
product that customers need and can trust and by providing an
innovative network marketing program which offers a fair and
balanced compensation plan for both the average and ambitious
MyNyloxin Independent Entrepreneur," he concluded.
In September 2012, Nutra Pharma announced the beginning of
distribution efforts by the TCN group of direct distributors. Since
that time, TCN has worked diligently to introduce Nyloxin® to
approximately 40,000 distributors in the United States and almost
400,000 distributors globally. TCN has now created a stand-alone
opportunity for distributors under the name MyNyloxin. The launch
begins today and will take place throughout the month of December.
The launch includes webinars, internet, radio and television
advertising.
Nyloxin® is an over-the-counter (OTC) pain reliever clinically
proven to treat moderate to severe (Stage 2) chronic
pain. Nyloxin® is currently available in the United States as
an oral spray for treating back pain, neck aches, headaches, joint
pain, migraines, and neuralgia, and as a topical gel for treating
joint pain, neck pain, arthritis pain, and pain from repetitive
stress. In addition to its everyday strength formulation, Nyloxin®
is also offered in an extra strength formula for more advanced,
Stage 3, chronic pain. The Company recently announced the beginning
of marketing efforts by New Vitality for the Direct Response and
retail marketing of Nyloxin. New Vitality's first Nyloxin
television commercials are scheduled to begin shortly.
About Nutra Pharma Corp. Nutra Pharma Corporation operates as a
biotechnology company specializing in the acquisition, licensing,
and commercialization of pharmaceutical products and technologies
for the management of neurological disorders, cancer, autoimmune,
and infectious diseases, including Multiple Sclerosis (MS), Human
Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain.
Additionally, the Company markets several drug products for sale
for the treatment of pain under the brands Cobroxin® and Nyloxin®.
For additional information about Nutra Pharma, visit:
http://www.NutraPharma.com or http://www.Nyloxin.com.
SEC Disclaimer This press release contains forward-looking
statements. The words or phrases "would be," "will allow," "intends
to," "will likely result," "are expected to," "will continue," "is
anticipated," "estimate," "project," or similar expressions are
intended to identify "forward-looking statements." Actual results
could differ materially from those projected in Nutra Pharma's
("the Company") business plan. The launch of MyNyloxin.com should
not be construed as an indication in any way whatsoever of the
future value of the Company's common stock or its financial value.
The Company's filings may be accessed at the SEC's Edgar system at
www.sec.gov. Statements made herein are as of the date of this
press release and should not be relied upon as of any subsequent
date. The Company cautions readers not to place reliance on such
statements. Unless otherwise required by applicable law, we do not
undertake, and we specifically disclaim any obligation, to update
any forward-looking statements to reflect occurrences,
developments, unanticipated events or circumstances after the date
of such statement.
Nutra Pharma (CE) (USOTC:NPHC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nutra Pharma (CE) (USOTC:NPHC)
Historical Stock Chart
From Sep 2023 to Sep 2024